Literature DB >> 12928048

Increased concentrations of homocysteine and asymmetric dimethylarginine and decreased concentrations of nitric oxide in the plasma of patients with Alzheimer's disease.

M L Selley1.   

Abstract

Vascular risk factors increase the risk of developing Alzheimer's disease. Increased concentrations of circulating homocysteine are associated with an increased risk of both vascular disease and Alzheimer's disease. Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of nitric oxide synthase. There is an increase in the concentration of ADMA in the circulation in vascular disease. We measured the concentrations of homocysteine, ADMA and nitric oxide (as nitrate and nitrite) in the plasma of 25 patients with Alzheimer's disease and 25 control subjects. There was a highly significant increase in the plasma concentration of homocysteine (P<0.001) and ADMA (P<0.0001) and a highly significant decrease in the plasma concentration of nitric oxide (P<0.0001) among the Alzheimer's patients. In the combined patient and control groups a highly significant positive correlation was found between the plasma concentrations of homocysteine and ADMA (r=0.782, P<0.0001). In addition, significant negative correlations were detected between the plasma concentration of nitric oxide and the plasma concentration of homocysteine (r=-0.592, P<0.0001) and ADMA (r=-0.789, P<0.0001). These significant correlations were found to persist, even when they were restricted to the Alzheimer's patients. The inhibition of endothelial nitric oxide synthesis by ADMA impairs cerebral blood flow, which may contribute to the development of Alzheimer's disease. Endothelial dysfunction is also associated with atherosclerosis and stroke, which are important risk factors for Alzheimer's disease. Inflammation plays an important role in Alzheimer's disease and the inhibition of endothelial nitric oxide by ADMA may increase the concentration of inflammatory mediators in the brain. The inhibition of neuronal nitric oxide synthesis by ADMA may cause cognitive dysfunction in Alzheimer's disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12928048     DOI: 10.1016/s0197-4580(03)00007-1

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  39 in total

1.  Presymptomatic Dutch-Type Hereditary Cerebral Amyloid Angiopathy-Related Blood Metabolite Alterations.

Authors:  Pratishtha Chatterjee; Anne M Fagan; Chengjie Xiong; Matthew McKay; Atul Bhatnagar; Yunqi Wu; Abhay K Singh; Kevin Taddei; Ian Martins; Samantha L Gardener; Mark P Molloy; Gerhard Multhaup; Colin L Masters; Peter R Schofield; Tammie L S Benzinger; John C Morris; Randall J Bateman; Steven M Greenberg; Marieke J H Wermer; Mark A van Buchem; Hamid R Sohrabi; Ralph N Martins
Journal:  J Alzheimers Dis       Date:  2021       Impact factor: 4.472

Review 2.  Is hyperhomocysteinemia an Alzheimer's disease (AD) risk factor, an AD marker, or neither?

Authors:  Jia-Min Zhuo; Hong Wang; Domenico Praticò
Journal:  Trends Pharmacol Sci       Date:  2011-06-20       Impact factor: 14.819

Review 3.  Recent advances in research on nitrergic nerve-mediated vasodilatation.

Authors:  Noboru Toda; Tomio Okamura
Journal:  Pflugers Arch       Date:  2014-10-23       Impact factor: 3.657

Review 4.  Physiological geroscience: targeting function to increase healthspan and achieve optimal longevity.

Authors:  Douglas R Seals; Jamie N Justice; Thomas J LaRocca
Journal:  J Physiol       Date:  2015-03-11       Impact factor: 5.182

Review 5.  Protein arginine methylation: from enigmatic functions to therapeutic targeting.

Authors:  Qin Wu; Matthieu Schapira; Cheryl H Arrowsmith; Dalia Barsyte-Lovejoy
Journal:  Nat Rev Drug Discov       Date:  2021-03-19       Impact factor: 84.694

Review 6.  Hyperhomocysteinemia impairs regional blood flow: involvements of endothelial and neuronal nitric oxide.

Authors:  Noboru Toda; Tomio Okamura
Journal:  Pflugers Arch       Date:  2016-07-14       Impact factor: 3.657

7.  Protective role of S-nitrosoglutathione (GSNO) against cognitive impairment in rat model of chronic cerebral hypoperfusion.

Authors:  Je-Seong Won; Jinsu Kim; Balasubramaniam Annamalai; Anandakumar Shunmugavel; Inderjit Singh; Avtar K Singh
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

8.  Dimethylarginine levels in cerebrospinal fluid of hyperacute ischemic stroke patients are associated with stroke severity.

Authors:  Raf Brouns; Bart Marescau; Ilse Possemiers; Rishi Sheorajpanday; Peter P De Deyn
Journal:  Neurochem Res       Date:  2009-03-19       Impact factor: 3.996

9.  One-carbon metabolism and Alzheimer's disease: focus on epigenetics.

Authors:  Fabio Coppedè
Journal:  Curr Genomics       Date:  2010-06       Impact factor: 2.236

10.  Asymmetric dimethylarginine is strongly associated with cognitive dysfunction and brain MR spectroscopic abnormalities in cirrhosis.

Authors:  Jasmohan S Bajaj; Vishwadeep Ahluwalia; James B Wade; Arun J Sanyal; Melanie B White; Nicole A Noble; Pamela Monteith; Michael Fuchs; Richard K Sterling; Velimir Luketic; Iliana Bouneva; Richard T Stravitz; Puneet Puri; Kenneth A Kraft; Hochong Gilles; Douglas M Heuman
Journal:  J Hepatol       Date:  2012-08-11       Impact factor: 25.083

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.